Addex Therapeutics Ltd (ADXN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Addex Therapeutics Ltd (ADXN) has a cash flow conversion efficiency ratio of -0.128x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-608.40K) by net assets ($4.77 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Addex Therapeutics Ltd to measure how much of total assets are equity-financed.
Addex Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Addex Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Addex Therapeutics Ltd cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Addex Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Addex Therapeutics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Longvie SA
BA:LONG
|
-0.060x |
|
Spectrumone publ AB
ST:SPEONE
|
-0.116x |
|
Green Technology Metals Ltd
AU:GT1
|
-0.017x |
|
Qlife Holding AB
ST:QLIFE
|
-2.207x |
|
Gungnir Resources Inc
V:GUG
|
-0.011x |
|
Battery Age Minerals Ltd
AU:BM8
|
-0.053x |
|
cbdMD Inc
NYSE MKT:YCBD
|
-0.115x |
|
WH Smith PLC
LSE:SMWH
|
-0.025x |
Annual Cash Flow Conversion Efficiency for Addex Therapeutics Ltd (2006–2025)
The table below shows the annual cash flow conversion efficiency of Addex Therapeutics Ltd from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Addex Therapeutics Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.77 Million | $-2.08 Million | -0.435x | +21.58% |
| 2024-12-31 | $9.68 Million | $-5.37 Million | -0.555x | +92.04% |
| 2023-12-31 | $1.15 Million | $-7.99 Million | -6.977x | -108.55% |
| 2022-12-31 | $4.91 Million | $-16.44 Million | -3.346x | -285.22% |
| 2021-12-31 | $16.93 Million | $-14.71 Million | -0.869x | -4.18% |
| 2020-12-31 | $14.61 Million | $-12.18 Million | -0.834x | -124.41% |
| 2019-12-31 | $25.52 Million | $-9.48 Million | -0.372x | -932.20% |
| 2018-12-31 | $39.24 Million | $1.75 Million | 0.045x | +102.81% |
| 2017-12-31 | $1.34 Million | $-2.13 Million | -1.590x | +87.10% |
| 2016-12-31 | $218.59K | $-2.69 Million | -12.326x | -680.44% |
| 2015-12-31 | $1.66 Million | $-2.63 Million | -1.579x | -105.86% |
| 2014-12-31 | $2.35 Million | $-1.80 Million | -0.767x | +85.28% |
| 2013-12-31 | $3.03 Million | $-15.78 Million | -5.214x | -188.38% |
| 2012-12-31 | $16.29 Million | $-29.45 Million | -1.808x | -130.40% |
| 2011-12-31 | $33.84 Million | $-26.55 Million | -0.785x | -61.27% |
| 2010-12-31 | $64.41 Million | $-31.34 Million | -0.487x | +4.14% |
| 2009-12-31 | $77.58 Million | $-39.38 Million | -0.508x | -239.45% |
| 2008-12-31 | $118.99 Million | $-17.79 Million | -0.150x | +36.53% |
| 2007-12-31 | $140.11 Million | $-33.00 Million | -0.236x | +49.08% |
| 2006-12-31 | $42.28 Million | $-19.56 Million | -0.463x | -- |
About Addex Therapeutics Ltd
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-in… Read more